Abstract | BACKGROUND: OBJECTIVE/METHODS: We performed a literature search to review available preclinical and clinical data that has led to the recent FDA approval of raloxifene as a chemopreventive agent for breast cancer in postmenopausal women. RESULTS/CONCLUSIONS:
|
Authors | Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Ranuccio Nuti |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 7
Issue 3
Pg. 259-70
(May 2008)
ISSN: 1744-764X [Electronic] England |
PMID | 18462184
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anticarcinogenic Agents
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Raloxifene Hydrochloride
|
Topics |
- Animals
- Anticarcinogenic Agents
(adverse effects, pharmacology, therapeutic use)
- Breast Neoplasms
(prevention & control)
- Estrogen Antagonists
(adverse effects, pharmacology, therapeutic use)
- Female
- Humans
- Postmenopause
- Raloxifene Hydrochloride
(adverse effects, pharmacology, therapeutic use)
- Selective Estrogen Receptor Modulators
(adverse effects, pharmacology, therapeutic use)
|